Literature DB >> 34671913

Assessment of the Burden of Small Intestinal Bacterial Overgrowth (SIBO) in Patients After Oesophagogastric (OG) Cancer Resection.

K-V Savva1, L Hage1, I Belluomo1, P Gummet2, P R Boshier1, C J Peters3.   

Abstract

Entities:  

Keywords:  GHBT; Gastrointestinal surgery; Quality of life; SIBO

Mesh:

Year:  2021        PMID: 34671913      PMCID: PMC9021082          DOI: 10.1007/s11605-021-05177-w

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


× No keyword cloud information.

Introduction

Small intestinal bacterial overgrowth (SIBO) is characterised by a change in the number/type of bacteria within the small intestine and is a common feature of patients who have undergone gastroesophageal reconstruction.[1] Symptoms of SIBO are characterised as non-specific and range from bloating to malnutrition. The aim of the current study is to determine the prevalence of SIBO in oesophagogastric cancer (OGC) resected patients and to investigate the impact of this disorder on gastrointestinal (GI) symptoms and HRQoL.

Methods

Patients who had previously undergone oesophagectomy (n = 30) and gastrectomy (n = 15) for gastroesophageal cancer, regardless of current GI symptoms, were recruited. Inclusion criteria were age ≥ 18 years, ≥ 1 year after surgery and free from disease recurrence at the time of assessment. Participants unable to provide informed written consent, suffering from liver disease, active infection, diabetes or had received antibiotic therapy within the previous four weeks, were excluded. A standard glucose hydrogen breath test (GHBT) using the GastroGastro + breath analyser was performed in all patients to assess SIBO occurrence. Current digestive symptoms were assessed in all patients using validated questionnaires evaluating overall digestive health and quality of life. Statistical analysis was performed using GraphPad Prism (version 7.0, La Jolla, CA, USA), Chi-squared tests and T-tests were used for univariate comparisons between GHBT( +) and ( −) patients responses. A P-value < 0.05 was considered to be statistically significant.

Results

Of the 190 patients who were approached to participate in this study, 45 met the inclusion criteria (Table 1). SIBO is a significant clinical concern after foregut surgery as supported by the high incidence (73.5%) of SIBO( +) patients in the tested cohort. Rates of positive GHBT were equivalent in patients who underwent oesophagectomy (73.33%, n = 22) and gastrectomy (73.33%, n = 22). Likewise, time since surgery, chemotherapy, alcohol consumption, smoking, use of proton pump inhibitors, BMI and years from surgery did not significantly influence the data, suggesting that these variables were not confounding factors in the current study. Mean digestive symptoms scores reported by the EORTC-QLQ-C30, questionnaire, were not significantly different between GHBT( +) and GHBT( −) patients (Table 2). Within the EORTC-QLQ-C30 questionnaire, there was a non-significant trend towards greater ‘appetite loss’ amongst GHBT( +) patients (24.1 ± 31.9 vs. 9.1 ± 21.5; P = 0.160) (Table 2).
Table 1

Demographics of post GI surgery participants

GHBT − n = 12GHBT + n = 33P-value
Sex (male:female)10:227:6 > 0.999
Age56.92 ± 16.8770.94 ± 9.120.003a
BMI (kg/m2)24.95 ± 5.6524.43 ± 4.220.724 b
PPI usage5 (55.56)17 (51.52)0.079
Smoking01 (3.23) > 0.999
Alcohol usage5 (55.56)21 (72.41)0.306
Chemotherapy9 (81.8)28 (84.85)0.661
Interval from surgery (years)7.59 ± 2.717.89 ± 3.50.945b
Surgical technique
  Two stage oesophagectomy6 (50.00)14 (42.42)
  Three stage oesophagectomy2 (16.67)8 (24.24)
  Subtotal gastrectomy04 (12.12)
Total gastrectomy4(33.33)7 (21.21) > 0.999

Fisher’s exact test was used to determine the P-value, except for (a) which was determined by Kruskal–Wallis test, (b) by chi-square test and (c) by Mann–Whitney U test. STDEV standard deviation, BMI biomass index, PPI proton-pump inhibitors

Table 2

EORTC QLQ-C30

All patientsn = 43GHBT ( +)n = 32GHBT ( −)n = 11P value1
Global health status69.6 ± 19.469.1 ± 19.471.2 ± 20.20.227
Physical functioning85.4 ± 17.483.5 ± 16.890.9 ± 18.70.057
Role functioning84.1 ± 23.180.2 ± 25.295.5 ± 7.80.361
Emotional functioning76.6 ± 25.074.5 ± 27.682.6 ± 14.70.111
Cognitive functioning81.0 ± 21.478.6 ± 22.187.9 ± 18.40.221
Social functioning79.5 ± 27.977.1 ± 29.686.4 ± 22.10.347
Fatigue33.1 ± 27.135.4 ± 29.426.3 ± 18.10.339
Nausea and vomiting11.9 ± 23.414.1 ± 24.46.1 ± 20.10.340
Pain17.8 ± 23.418.8 ± 25.315.2 ± 17.40.665
Dyspnoea20.2 ± 25.322.9 ± 26.112.1 ± 22.50.227
Insomnia33.3 ± 29.136.5 ± 30.924.2 ± 21.60.234
Appetite loss20.2 ± 30.124.1 ± 31.99.1 ± 21.50.160
Constipation10.8 ± 22.710.4 ± 24.612.1 ± 27.10.832
Diarrhoea23.3 ± 25.824.1 ± 25.721.2 ± 27.10.764
Financial difficulties17.1 ± 30.521.4 ± 34.26.1 ± 13.50.159

Results are presented as mean ± standard deviation

1Comparison across different patient groups was performed by t-test

Demographics of post GI surgery participants Fisher’s exact test was used to determine the P-value, except for (a) which was determined by Kruskal–Wallis test, (b) by chi-square test and (c) by Mann–Whitney U test. STDEV standard deviation, BMI biomass index, PPI proton-pump inhibitors EORTC QLQ-C30 Results are presented as mean ± standard deviation 1Comparison across different patient groups was performed by t-test

Discussion

The current study provides valuable new insights for SIBO after surgery for OGC. The high rate of suspected SIBO in GHTB( +) patients suggests that the burden of this condition is under reported after OGC surgery.[1,2] Patient reported outcomes suggest that the manifestations of SIBO are nonspecific and include a range of symptoms that overlap with other digestive disorders .[3] GHBT was used to diagnose SIBO in this study. Two principal breath tests have been developed for the diagnosis of SIBO: GHBT and lactulose HBT, the latter requiring the administration of lactulose as opposed to glucose.[4] The low sensitivity that is seen with both the GHBT and LHBT, with LHBT having a lower specificity and sensitivity than GHBT for SIBO diagnosis,[5] would tend to result in a higher false negative rate. This indicates that SIBO may in fact be underdiagnosed in populations assessed by these methods. Potential reasons for false positive results include colonic fermentation gas production and rapid intestinal transit.[6]. The possibility of underestimating SIBO( +) patients by the use of HBTs further supports that SIBO is a significant concern upon OG resection, as SIBO prevalence might actually be greater than 73.5%. In summary, this study (i) has demonstrated that SIBO does not exhibit specific clinical symptoms thus making its clinical diagnosis even more difficult and (ii) emphasised the need to determine appropriate guidelines for its assessment and treatment after OGC resection.
  6 in total

1.  Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance.

Authors:  Amit H Sachdev; Mark Pimentel
Journal:  Ther Adv Chronic Dis       Date:  2013-09       Impact factor: 5.091

2.  The role of small intestinal bacterial overgrowth in postgastrectomy patients.

Authors:  C N Paik; M-G Choi; C H Lim; J M Park; W C Chung; K-M Lee; K-H Jun; K Y Song; H M Jeon; H-M Chin; C H Park; I-S Chung
Journal:  Neurogastroenterol Motil       Date:  2011-02-16       Impact factor: 3.598

Review 3.  Small Intestinal Bacterial Overgrowth and Other Intestinal Disorders.

Authors:  Uday C Ghoshal; Ujjala Ghoshal
Journal:  Gastroenterol Clin North Am       Date:  2017-03       Impact factor: 3.806

4.  Utility of hydrogen breath tests in diagnosis of small intestinal bacterial overgrowth in malabsorption syndrome and its relationship with oro-cecal transit time.

Authors:  Uday C Ghoshal; Ujjala Ghoshal; Kshaunish Das; Asha Misra
Journal:  Indian J Gastroenterol       Date:  2006 Jan-Feb

5.  Production, metabolism, and excretion of hydrogen in the large intestine.

Authors:  S U Christl; P R Murgatroyd; G R Gibson; J H Cummings
Journal:  Gastroenterology       Date:  1992-04       Impact factor: 22.682

6.  Breath Tests for the Non-invasive Diagnosis of Small Intestinal Bacterial Overgrowth: A Systematic Review With Meta-analysis.

Authors:  Giuseppe Losurdo; Gioacchino Leandro; Enzo Ierardi; Francesco Perri; Michele Barone; Mariabeatrice Principi; Alfredo Di Leo
Journal:  J Neurogastroenterol Motil       Date:  2020-01-30       Impact factor: 4.924

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.